Current treatments, practical management, and emerging investigational therapies for myelofibrosis
Current treatments, practical management, and emerging investigational therapies for myelofibrosis.
The article reviews current diagnostic frameworks, prognostic models, and treatment strategies for myelofibrosis, including approved JAK inhibitors and emerging investigational therapies. It highlights advances in understanding the molecular pathogenesis, particularly JAK‑STAT signaling, and discusses emerging drug classes, next‑generation JAK inhibitors, mutant calreticulin antibodies, and the evolving management of cytopenias and advanced disease.
This article outlines the therapeutic landscape for a hematologic malignancy that remains largely incurable, emphasizing emerging treatments that could shift standard care and improve patient outcomes.
Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Kapcsolódó jelek
- ASH 2024: New Research, Data Drive Progress in Myelofibrosis
- Single agent selinexor is active in patients with myelofibrosis refractory or intolerant to JAK inhibitors
- Population Pharmacokinetics and Exposure‑Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis
- SOHO 2026: Imetelstat Efficacy in Myelofibrosis - GERN
- The German ONKOPEDIA Guideline for Myelofibrosis in 2025—Recommendations of an MPN Expert Panel